Ilya Rachman
Directeur Général chez IMMIX BIOPHARMA, INC.
Fortune : 2 M $ au 30/04/2024
Postes actifs de Ilya Rachman
Sociétés | Poste | Début | Fin |
---|---|---|---|
IMMIX BIOPHARMA, INC. | Directeur Général | 01/01/2012 | - |
Président | 01/01/2012 | - | |
Fondateur | 01/01/2012 | - | |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Président | - | - |
Historique de carrière de Ilya Rachman
Formation de Ilya Rachman
University of Illinois | Doctorate Degree |
University of Iowa | Undergraduate Degree |
University of California, Los Angeles | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Chairman | 2 |
Chief Executive Officer | 1 |
Founder | 1 |
Sectorielle
Consumer Services | 4 |
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
IMMIX BIOPHARMA, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Bourse
- Insiders
- Ilya Rachman
- Expérience